This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Medical Tech Company Tornier (TRNX) Is Flatlining

NEW YORK (TheStreet) -- Medical technology developer Tornier N.V. (TRNX) flatlined after reporting third-quarter results which disappointed on the top and bottom line. Shares have plummeted 24.1% to $16.07.

The Dutch company recorded a loss of 18 cents a share on revenue of $66.7 million. Though revenue was up 15.1% on the year-ago quarter, it failed to meet Wall Street's expectations. Analysts surveyed by Thomson Reuters were looking for a loss of 14 cents a share on $70.35 million in revenue.

Revenue in the U.S., which accounts 61% of global revenue, dropped 1.8% compared to the prior year.

For the fourth quarter, the company projects revenue between $73 million to $77 million, significantly lower than the $86.49 million analysts had hoped for. Full-year revenue is expected in the range of $299.2 million to $303.2 million, compared to Wall Street's forecast of $317.38 million.

Must Read: Office Depot (ODP) and OfficeMax (OMX) Merge: What You Need to Know

TheStreet Ratings team rates Tornier N.V. as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:

"We rate Tornier N.V. (TRNX) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and weak operating cash flow."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TRNX $20.67 1.37%
AAPL $109.50 -1.16%
FB $92.47 0.08%
GOOG $639.16 -0.50%
TSLA $226.72 -2.26%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs